Cargando…

Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort

INTRODUCTION: Gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs). The objective of the study was to evaluate risk factors associated with acute kidney injury (AK...

Descripción completa

Detalles Bibliográficos
Autor principal:	Perez-Ruiz, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696294/ https://www.ncbi.nlm.nih.gov/pubmed/28956324 http://dx.doi.org/10.1007/s40744-017-0082-2

Ejemplares similares

Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2021)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021)

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
por: Jeong, Hoon, et al.
Publicado: (2022)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study
por: Slobodnick, Anastasia, et al.
Publicado: (2020)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation
por: Gois, Pedro Henrique França, et al.
Publicado: (2017)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2022)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
por: Rey, Amayelle, et al.
Publicado: (2019)

Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”
por: Huang, Jin-Xian, et al.
Publicado: (2023)

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study
por: Kok, Victor C., et al.
Publicado: (2014)

Illness perceptions of gout patients and the use of allopurinol in primary care: baseline findings from a prospective cohort study
por: Walsh, Ciaran P., et al.
Publicado: (2016)

Association Between Gout and Injury Risk: A National Retrospective Cohort Study
por: Ou, Shih-Hsiang, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Retraction Note: Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2023)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol
por: van Leeuwen, Kevin D B, et al.
Publicado: (2018)

Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study
por: Søltoft Larsen, Kasper, et al.
Publicado: (2016)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study
por: Rodríguez-Martín, Sara, et al.
Publicado: (2019)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population
por: Zhang, Keke, et al.
Publicado: (2019)

Authors’ Reply to Huang and Zhang: Comment on “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”
por: Tong, Qiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m7sigvcj8brn92sh4om66q41lc